Clinical Trial Update: A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept study comparing AIN457, ACZ885, and corticosteroids in polymyalgia rheumatica; trial terminated with posted results in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polymyalgia Rheumatica

Drugs mentioned

• ACZ885 (canakinumab)
• AIN457
• Corticosteroids (corticosteroids)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Polymyalgia Rheumatica, Inflammatory Diseases | Phase 2 | Status: TERMINATED | Results posted: 2015-03-04